Cell cycle regulators and their abnormalities in breast cancer
Open Access
- 1 December 1998
- journal article
- review article
- Published by BMJ in Molecular Pathology
- Vol. 51 (6) , 305-309
- https://doi.org/10.1136/mp.51.6.305
Abstract
One of the main properties of cancer cells is their increased and deregulated proliferative activity. It is now well known that abnormalities in many positive and negative modulators of the cell cycle are frequent in many cancer types, including breast carcinomas. Abnormalities such as defective function of the retinoblastoma gene and cyclin-dependent kinase inhibitors (for example, p16, p21, and p27), as well as upregulation of cyclins, are often seen in breast tumours. These abnormalities are sometimes coincidental, and newly described interplays between them suggest the existence of a complex regulatory web in the cell cycle.Keywords
This publication has 77 references indexed in Scilit:
- How viral oncogenes make the cell cycleTrends in Genetics, 1996
- Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesionsNature Medicine, 1995
- Expression of the cyclin‐dependent kinase inhibitors p16INK4, p15INK4B and p21Waf1/cip1 in human breast cancerInternational Journal of Cancer, 1995
- Cyclin D1 as a cellular proto-oncogeneSeminars in Cancer Biology, 1995
- Cyclins and cancer II: Cyclin D and CDK inhibitors come of ageCell, 1994
- Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic miceNature, 1994
- A Cell Cycle Regulator Potentially Involved in Genesis of Many Tumor TypesScience, 1994
- A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4Nature, 1993
- WAF1, a potential mediator of p53 tumor suppressionCell, 1993
- Molecular cloning and chromosomal mapping of DNA rearranged with the parathyroid hormone gene in a parathyroid adenoma.Journal of Clinical Investigation, 1989